The DOI matches its Crossref record; 121 of the 128 references it cites were found in a registry or an index; 143 of the 228 sources its claims cite were checked for support.
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Open accessAbstract
Review of major molecular alterations in pancreatic cancer.
Overview
CoChat Summary
TL;DR
This is a narrative review of the roles of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer, emphasizing how their alterations shape tumor biology, prognosis and potential targeted treatment strategies. It argues that molecular profiling can support risk assessment, early detection and more personalized therapy, but also shows that many of these biomarkers still need further validation.
Key findings
- TP53 mutations are reported in 50–90% of pancreatic ductal adenocarcinomas and in 60–70% of cases in another section; they are linked to carcinogenesis, chemotherapy resistance and prognosis. TP53 mutations were also reported across pancreatic lesions, from 9.1% of intermediate-grade IPMNs to 75% of invasive ductal adenocarcinomas.
- CDKN2A alterations are described as common and clinically relevant: somatic mutations are reported in up to 95% of pancreatic tumors, and in TCGA analysis patients with CDKN2A mutations or deep deletions had poorer overall survival and primary therapy outcomes. The paper also states that CDKN2A-inactivated PDAC showed increased sensitivity to paclitaxel and SN-38.
- SMAD4/DPC4 loss is repeatedly associated with worse outcomes and metastasis. In one PDAC cohort of 249 patients, 43% lacked SMAD4 expression and 45% were positive; intact SMAD4 expression was associated with median survival of 19.2 months versus 14.7 months without SMAD4. In another cohort of 348 PDAC patients, 53% had DPC4/Smad4 expression loss.
- KRAS is the most frequently mutated gene in pancreatic cancer, reported at 90–95% in pancreatic adenocarcinomas and near 100% in PDAC in one section. The review also notes studies where KRAS mutations were found in 74.7% of EUS-FNA samples and 62.6% of ctDNA samples, and that ctDNA KRAS mutations were associated with shorter median survival.
Methods
- Narrative review of published studies on the molecular biology, prognosis and therapeutic targeting of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer.
- The paper synthesizes findings from human cohorts, TCGA/bioinformatics analyses, liquid biopsy studies, and preclinical mouse/cell line experiments.
- Main analysis is qualitative integration of reported mutation frequencies, survival associations, and treatment-response observations across the cited literature.
Limitations
- The paper does not describe a systematic review protocol, search strategy, inclusion criteria, or meta-analysis; this is evident from the text.
- The review itself notes that the prognostic impact of some markers remains unsettled, e.g. CDKN2A mutations are “still being investigated” and the impact on treatment response “requires further exploration.”
- It also states that SMAD4 effects on chemotherapy response may vary by treatment regimen and disease stage, indicating incomplete or context-dependent evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Modifiable factors include smoking, alcohol, obesity and dietary factors, where red meat increases risk, while vegetables and fruits offer protection. Non-modifiable risk factors comprise gender, age (with increased risk after 50), ethnicity, diabetes, family history, genetic factors, chronic infections and ABO blood group (non-O associated with higher risk). Created with BioRender.com (accessed on 27 February 2024) [13].](https://figures.cochat.ai/paper-figures/1e688da2d762458a9850f21c4797fbbf/significance-of-tp53-cdkn2a-smad4-and-kras-in-pancreatic-cancer-figure-1.jpg)


Verification
Claims the paper makes
106 Valid · 3 Not valid · 52 Not checked · 2 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“This multifunctional protein also facilitates the activation of receptor-regulated SMADs (R-SMADs), including SMAD3 and SMAD1, highlighting its role in orchestrating downstream events [62,81].”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 4. SMAD4 > 4.1. TGF-β Signaling and Tumor Suppression/Promotion
What the sources say
- Supportedcites [62] Liu, L., Li, Q., Yang, L., Li, Q., and Du, X. (2021). SMAD4 Feedback Activates the Canonical TGF-β Family Signaling Pathways. Int. J. Mol. Sci., 22. source
The Discussion states that SMAD4 induced R-SMAD activity by increasing phosphorylation in porcine granulosa cells, naming p-SMAD3 and p-SMAD1. It qualifies the evidence: p-SMAD3 was reported in a previous study, while the p-SMAD1 result was from ongoing research with data not shown. (LLM, conf=0.88)
- Disputedcites [81] Zhao, 2018, The role of TGF-β/SMAD4 signaling in cancer, Int. J. Biol. Sci. sourceExperimental — accuracy not yet measured
In “The role of SMAD4 in TGF-β signaling pathway” (page not provided), the paper identifies SMAD1 and SMAD3 as R-SMADs but describes their activation in the opposite order from the claim: the receptor phosphorylates SMAD2/3 before they form a complex with SMAD4. It describes SMAD4 as a mediator of downstream signaling, not as facilitating R-SMAD activation. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The TP53 mutational status-based genomic signature emerges as a critical factor for disease prognosis and therapeutic responses.”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 2. TP53 > 2.2. TP53 Mutations and Poor Prognosis
What the sources say
- Supportedcites [21] Zhang, F., Zhong, W., Li, H., Huang, K., Yu, M., and Liu, Y. (2021). TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. Front. Cell Dev. Biol., 9. source
The Discussion states that the TP53-associated signature can stratify prognosis and serve as a therapeutic indicator in pancreatic cancer. The Results also say it might guide selection of chemotherapeutic agents, supporting the claim about therapeutic responses in that disease. (LLM, conf=0.91)
- Not checked yetcites [22] Liu, 2022, A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer, Math. Biosci. Eng. source
Checked before — its earlier verdict is held back until a new check runs.
- Partly supportedcites [23] Liu, X., Chen, B., Chen, J., and Sun, S. (2021). A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer. BMC Cancer, 21. sourceExperimental — accuracy not yet measured
The Results report that TP53-mutated patients had significantly worse overall survival in three pancreatic cancer cohorts, and the Discussion describes a seven-gene TP53-related signature for prognosis prediction. The cited passages do not establish that the signature predicts therapeutic responses. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genetic analysis indicates complex interactions among KRAS, CDKN2A, TP53 and SMAD4 alterations, influencing metastatic burden and survival [26].”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 2. TP53 > 2.2. TP53 Mutations and Poor Prognosis
What the sources say
- Supportedcites [26] Yachida, 2012, Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors, Clin. Cancer Res. source
The Results section (page unavailable in our copy) describes patterns of coexisting KRAS, CDKN2A, TP53 and SMAD4 alterations. It reports that the number of altered driver genes was significantly correlated with metastatic burden, disease-free survival and overall survival. The claim is supported as an association; the study does not establish causation. (LLM, conf=0.91)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Pancreatic cancer commonly features mutations in key genes, such as KRAS, p16/CDKN2A, TP53 and SMAD4/DPC4 [3,4,5] (Table 1).”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [3] Maitra, 2008, Pancreatic cancer, Annu. Rev. Pathol. source
- Supportedcites [4] Saiki, Y., Jiang, C., Ohmuraya, M., and Furukawa, T. (2021). Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. Cancers, 14. source
The Introduction identifies KRAS, CDKN2A, TP53 and SMAD4 as the four main genetic drivers of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Sections 2.1, 2.4 and 2.5 further describe alterations in KRAS, SMAD4 and CDKN2A; section 2.5 identifies p16 as a CDKN2A product. (LLM, conf=0.91)
- Supportedcites [5] Hu, 2021, Mutations in key driver genes of pancreatic cancer: Molecularly targeted therapies and other clinical implications, Acta Pharmacol. Sin. source
The Introduction names KRAS, CDKN2A, TP53, and SMAD4/DPC4 as the main driver genes in pancreatic cancer. Figure 1 identifies KRAS, CDKN2A, TP53, and SMAD4 as the most commonly mutated genes in the TCGA pancreatic-cancer dataset. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The accuracy of this genomic signature is underscored by its association with the immunophenotype of PDAC [21,22,23].”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 2. TP53 > 2.2. TP53 Mutations and Poor Prognosis
What the sources say
- Supportedcites [21] Zhang, F., Zhong, W., Li, H., Huang, K., Yu, M., and Liu, Y. (2021). TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. Front. Cell Dev. Biol., 9. source
The Discussion reports that the TP53-associated signature was an accurate, independently validated prognostic predictor and could reflect immune cell infiltration. The Results section on immune cell infiltration reports correlations between signature risk scores and specific immune-cell populations in pancreatic cancer. Together, these support the claimed association with immunophenotype, though the paper does not use the exact phrase ‘underscored by.’ No page numbers are available in our copy. (LLM, conf=0.88)
- Not checked yetcites [22] Liu, 2022, A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer, Math. Biosci. Eng. source
Checked before — its earlier verdict is held back until a new check runs.
- Supportedcites [23] Liu, X., Chen, B., Chen, J., and Sun, S. (2021). A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer. BMC Cancer, 21. source
The Results section, “Immune cell infiltration analysis and GSEA” (page unavailable), reports significant differences in immune-cell fractions between the signature’s high- and low-risk groups. The paper also reports prognostic performance for the signature; describing the immune association as underscoring its accuracy is the citing authors’ interpretation. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
66 more claims · 39 with their cited sources checked
Create a free account to see all 163 claims and to verify the 24 references still open.
- It may state two separate claims as one. 88
- Borderline: one of the tests for a substantial claim is unclear. 1
- Probably not a substantial claim. 4
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“A copy number analysis revealed recurrent gains and losses, implicating genes like MET and CDKN2A [87].”
BackgroundExosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Epidemiology of pancreatic cancer
Ilic, M., & Ilic, I. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i44.9694 · Cited by 1,301
Bloomston, M., Frankel, W. L., Petrocca, F., Volinia, S., Alder, H., Hagan, J. P., Liu, C.-G., Bhatt, D., Taccioli, C., & Croce, C. M. (2007) · JAMA · doi:10.1001/jama.297.17.1901 · Cited by 1,141
Phenotype and Genotype of Pancreatic Cancer Cell Lines
Deer, E. L., González-Hernández, J., Coursen, J. D., Shea, J. E., Ngatia, J., Scaife, C. L., Firpo, M. A., & Mulvihill, S. J. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181c15963 · Cited by 936 · cited 1×
“Discrepancies in the mutational status of TP53 and CDKN2A/p16 among cell lines caution researchers about discrepancies between laboratory-specific and literature-reported mutational statuses [20].”
BackgroundKRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
Epidemiology of pancreatic cancer: an overview
Raimondi, S., Maisonneuve, P., & Lowenfels, A. B. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.177 · Cited by 740
Regulation and function of the p53 tumor suppressor protein
Ryan, K. M., Phillips, A. C., & Vousden, K. H. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00216-7 · Cited by 721
Research works printed but not linked: 2
- (2023, December 26). CDKN2A Cyclin Dependent Kinase Inhibitor 2A [Homo Sapiens (Human)], Available online: https://www.ncbi.nlm.nih.gov/gene/1029.
- Lovely, 2023, Explorations Unearth New Potential of KRAS Mutations in Pancreatic Cancer, Oncol. Live, 24, 12
Cited by
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Yu, B., Shao, S., & Ma, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217350 · Cited by 131
Early Detection of Pancreatic Cancer: Current Advances and Future Opportunities
Lin, Z., Adeniran, E. A., Cai, Y., Qureshi, T. A., Li, D., Gong, J., Li, J., Pandol, S. J., & Jiang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13071733 · Cited by 44
Liu, R., Li, J., Liu, L., Wang, W., & Jia, J. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.07.004 · Cited by 39
Dahiya, D. S., Malik, S., Paladiya, R. D., Ahsan, S., Waseem, H., Bharadwaj, H. R., Goel, A., Jaan, A., Hayat, U., Hasan, F., et al. (2025) · Cancers · doi:10.3390/cancers17071085 · Cited by 23
Graham, S., Dmitrieva, M., Costa, D. B. V., Francescone, R., Trujillo, M. A. M., Cukierman, E., & Wood, L. D. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae064 · Cited by 19
Metadata
- Authors
- Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- First Department of Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
- University of California, Los Angeles (US)
- Corresponding author
- Toutouzas, Konstantinos G.
- ORCID
- Venue
- Current Issues in Molecular Biology
- Publisher
- MDPI AG
- Published
- 2024-03-23
- Volume
- 46
- Issue
- 4
- Pages
- 2827-2844
- ISSN
- 1467-3037 (ISSN-L)
- 1467-3045
- PMC
- PMC11049225
- OpenAlex
- W4393164529
- Cited by
- 110
- References
- 128
- Citations by year
- 2026: 55 · 2025: 42 · 2024: 13
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Current Issues in Molecular Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic cancer, TP53, CDKN2A, SMAD4, KRAS, tumor suppressor, p53 deficiency, prognostic value, targeted therapy, molecular signatures, cancer risk assessment, early detection, personalized treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. https://app.cochat.ai/papers/10.3390/cimb46040177
- The paper
- Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024). Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. Current Issues in Molecular Biology. https://doi.org/10.3390/cimb46040177
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.